Avandia Raises Heart-Death Risk: Study
Avandia (rosiglitazone), GlaxoSmithKline Plc's widely used drug for treating type 2 diabetes, increased the risk of heart death by 64 percent and the risk of heart attack by 43 percent, U.S. researchers said in the New England Journal of Medicine on Monday. Glaxo said it strongly disagreed with the conclusions of the report, which was based on an analysis of other studies.
详细信息
http://www.diabetes.org/diabetes ... utershealthEDIT.xml